Brief: Coya Therapeutics Announces FDA Acceptance Of Investigational New Drug (IND) Application
25/08/2025 13:23
Aug 25 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR COYA 302 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) COYA THERAPEUTICS INC - FDA APPROVAL TRIGGERS $4.2 MILLION PAYMENT TO COYA COYA THERAPEUTICS INC - FDA ACCEPTANCE ENABLES PHASE 2 STUDY OF COYA 302 IN PATIENTS WITH ALS Source text: ID:nPn2GfVs8a Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)